SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.70-0.8%Jan 23 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bluegreen who wrote (12404)12/7/1999 9:00:00 PM
From: aknahow  Read Replies (1) of 17367
 
"XOMA is making the HE method available for licensing to companies who may find it a preferable
alternative to other methods. XOMA is also using the HE method as part of the technology involved in
XOMA?s Genimune? targeted immunofusion molecule (TIF) program, and for the ING-1 antibody, both
available for licensing."

Wonder if XOMA will license either of these in my lifetime. If they do it might result in other companies having more interest in their humanization technology.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News